<DOC>
	<DOCNO>NCT02443571</DOCNO>
	<brief_summary>This retrospective observational multi center study establish collect clinical experience relate administration Fluciclovine 18F employ investigator initiated study name patient/compassionate use program 5 site .</brief_summary>
	<brief_title>Retrospective Observational Study Investigating Fluciclovine ( 18F ) ( FACBC )</brief_title>
	<detailed_description>This study collect clinical data consent patient ( unless HIPAA waiver equivalent grant ) receive PET radiotracer Fluciclovine 18F ( FACBC ) ( synthetic amino acid analog ) image patient various cancer participate site US Europe . Data collection cover baseline medical history medication patient . The result PET radiotracer image finding , report histopathology biopsied tissue ( available ) time window relevant use PET image diagnosis primary/recurrent prostate cancer record . In subject , regard safety monitoring , available data physical examination , vital sign laboratory test result collect 28 day prior 35 day window Fluciclovine 18F ( FACBC ) administration . The major goal investigation consolidate safety profile Fluciclovine 18F ( FACBC ) , evaluate use detection local extraprostatic recurrence prostate cancer evaluate ability detect malignancy patient undergo screen primary prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Patient manage site ethical committee approval retrospective data collection protocol receive Patient receive least one injection fluciclovine ( 18F ) detection malignant tumour location Subjects exclude analysis follow criterion meet : Patients participate clinical trial open access programme country sit participate study . Patients manage site without ethical committee approval retrospective data collection protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>observational study</keyword>
</DOC>